Klaria Pharma

Klaria will cooperate with EY to identify and establish contacts with potential strategic partners. The primary focus will be to secure a  partner for the sumatriptan product in both the EU and US - the company is expecting to receive market authorization on a number of European markets by Q3 2024. Additionally, the company will seek partnerships for the the international rights to the epinephrine film program (outside the U.S. where the rights have been licensed to Imbrium Therapeutics). Klaria will also consider partnerships or other agreements for the remaining projects including Klaria's alginate drug delivery technology.

All potential outcomes, including licensing or divestments, that could maximize shareholder value, will be considered.

The ambition is to reach agreements during autumn 2024.